Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4551)	8/27/2001 4:17:50 PM
From: Icebrg	Respond to of 52153

>>each sale is reported by both Vulcan and Kunath, likely becuase they are somehow affiliated.>> Ruth B. Kunath Vulcan Northwest, Inc. Ms. Kunath has served as a member of the board of directors of Ontogeny and subsequently of Curis since December 1998. Ms. Kunath has been biotechnology portfolio manager since 1992 for Vulcan Ventures, Incorporated, a venture capital firm founded by Paul G. Allen. Prior to her employment at Vulcan Ventures, Ms. Kunath spent nine years managing Seattle Capital Management Equity assets and eight years as the Senior Portfolio Manager for the healthcare sector of Bank of America Capital Management. Ms. Kunath has served as a director of Vaxgen, Inc., a biotechnology company, since June 1999 and Dendreon Corporation, a biotechnology company, since December 1999. Ms. Kunath received a BA from DePaul University and is a Certified Financial Analyst.